Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Lilly 1Q | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Lilly 1Q

Animal Health offsets lingering effects of patent expirations for Cymbalta and Evista

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Lilly

1Q Revenues: $4.6 billion (-1%)

1Q Earnings: $529.5 million (-27%)

Comments: Revenue in the U.S. increased 6% to $2.2 billion, driven by increased volumes for Cyramza (sales of $67.5 million), and the inclusion of revenue from Novartis Animal Health ($749.8 million, up 42%). Revenue outside the U.S. decreased 6% to $2.4 billion due to unfavorable impact of foreign exchange. Lingering effects of U.S. patent expirations for Cymbalta (-40% to $287 million) and Evista (-55% to $66.8 million) continue to negatively impact results. Zyprexa sales were down 22% to $219.5 million. Alimta sales were $573.0 million, down 9%. Cialis sales were up 1% to $538.3 million. Humalog sales were up 5% to 684.0 million.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters